Ferring Pharmaceuticals

Press Release

Ferring Presents $1,000 to Local Honorable Mention Winner

Jeff Burrows, Ferring Pharmaceuticals, presents Wendy and Doug Hurst, honorable mention winners of its My Little Miracle Essay Contest, with a $1,000 prize for their child, Hudson Robert, born with the help of Repronex™ (menotropins for injection, USP) - one of the Company’s fertility treatments.

Pictured from left to right: Doug Hurst; Hudson Robert Hurst; Wendy Hurst; and Jeff Burrows, Ferring Pharmaceuticals.

OAK BROOK, IL – November 30, 2004 – Oak Brook Fertility Center (OBFC) announced today that its patient, Wendy Hurst, and her husband, Doug, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for their entry in the Company’s My Little Miracle Essay Contest. Their entry, A Little Help, chronicled the path to their son’s birth. The prize money will be deposited into an education fund for Hudson Robert, their two-year-old son born with the help of Repronex™ (menotropins for injection, USP) – one of Ferring’s fertility treatments. The presentation was made on November 29th at the OBFC’s office in Oak Brook.

“We are so excited and grateful to receive an honorable mention scholarship!” said Wendy Hurst. “Thanks for your part in helping us achieve our dream of becoming a family.”

“A healthy baby born after years of infertility is, indeed, the most wonderful ‘little miracle’ for the parents as well as for the entire staff at OBFC,” added W. Paul Dmowski, M.D., Ph.D., Medical Director, OBFC. “I commend Ferring Pharmaceuticals for recognizing this in their contest and would like to compliment Wendy and Doug on their award-winning essay.”

The My Little Miracle Essay Contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,” added Jeff Burrows, reproductive and endocrine specialist, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

About the Hursts

The Hursts unsuccessfully tried to conceive for almost two years before they sought treatment. After a failed first attempt at conceiving with the help of fertility treatment, their physician, Dr. Dmowski, tried treatment with another type of medication. In the essay, Doug, Wendy’s husband, speaks of their experience:

He said ‘I love you Daddy’ on my work voice mail yesterday. Hudson is only 22 months old, so I suspect he had a little help from Mommy … you know, to at least dial the right number. Nothing wrong with a little help. We’ve been getting help every step of the way. The decision to have children was an easy one for us, but we were among a surprisingly large group who have high hopes for a family and lots of love to give but need a miracle to get there … We were ready for some help. After routine testing and a failed result …, [Dr. Dmowski] assured us, ‘With a little help from Repronex™, you will be pregnant within three months.’ A lofty claim, we thought. … it turned out that Repronex™ was the final piece of the puzzle for us. We were lucky enough to get immediate results. As fate would have it, getting pregnant in that first month turned out to be especially important. You see, Hudson arrived in time to meet my father who passed away exactly 23 days later after a long bout with cancer. Hudson is the joy of our lives. … P.S. Our second little ‘Repro Boy’ is on the way. We are planning on naming him Cooper when he arrives in February. We are hoping for a couple ‘Repro Girls’ in the future to balance things out.

**About Bravelle™ and Repronex™**

Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

About Oak Brook Fertility Center

Oak Brook Fertility Center (OBFC) is a state-of-the-art medical facility fully equipped to diagnose and treat infertility problems and reproductive disorders involving male, female, or both partners. At OBFC, their In Vitro Fertilization Program is entirely office-based and one of the first such facilities in the country. Their success rates have been consistently above the national average and one of the highest in the Midwest. The Center provides comfortable, modern facilities that have been granted full accreditation by healthcare organizations. OBFC physicians are double-board certified (Obstetrics/ Gynecology and Reproductive Endocrinology/ Infertility) and are recognized nationally and internationally in the field of reproductive endocrinology. For more information about OBFC, please visit www.oakbrookfertility.com.

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.